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OBJECTIVES:  Plasma melatonin profile abnormalities have been described in patients 
with cirrhosis and generally attributed to impaired hepatic melatonin metabolism.  The 
possibility that they might reflect circadian clock dysfunction has not been explored.  In 
addition, the relationship between plasma melatonin profiles and the sleep disturbances 
observed in these patients remains unclear.  The aims of this study were: i) to evaluate 
circadian clock function and hepatic melatonin metabolism in cirrhotic patients; ii) to 
study the relationship between plasma melatonin profiles and sleep-wake behaviour.   
METHODS:  The study population comprised 20 cirrhotic patients (59 [39-77] yr) and 
nine healthy volunteers (60 [38-84]).  Plasma melatonin/cortisol concentrations were 
measured hourly, for 24 hours, in light-/posture-controlled conditions.  Urinary 6-
sulphatoxymelatonin, the main melatonin metabolite, was measured simultaneously to 
determine clearance.  The ability of light to suppress nocturnal melatonin synthesis was 
assessed.  Habitual sleep quality/timing were evaluated using a questionnaire, 
actigraphy and sleep diaries.   
RESULTS:  There was evidence of central circadian disruption in the patients compared 
to the healthy controls: peak plasma melatonin/cortisol times were delayed (04:48±02:36 
vs. 02:48±00:54, p=0.01; 10:18±02:54 vs. 08:54±01:24, p=0.06) and the plasma melatonin 
response to light reduced (12±19 vs. 24±15%, p=0.09).  However, the mean 24-hour 
plasma melatonin clearance did not differ significantly between the patients and healthy 
volunteers (0.22±0.10 vs. 0.28±0.17 L/Kg/hr, p=0.36).  Finally, although patients showed 
a degree of misalignment between sleep and circadian timings, there was no association 
between circadian abnormalities and impaired sleep quality.   
CONCLUSIONS:  Plasma melatonin profile abnormalities, predominantly central in 
origin, are observed in patients with mild to moderately decompensated cirrhosis.  
However, they are substantially unrelated to the sleep disturbances prevalent in these 
patients.  
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INTRODUCTION 
The master circadian clock, which is located in the suprachiasmatic nuclei (SCN) of the 
hypothalamus, regulates sleep timing and other 24-hour, or circadian, behavioural, 
physiological and biochemical rhythms.  The average, endogenous circadian period is 
approximately 24.18 hr (1) and must be synchronized constantly to the 24-hour day by 
external influences.  Light is the major external time cue and reaches the SCN by afferent 
projections from the retina.  The SCN projects, in turn, to the pineal gland, regulating the 
production of melatonin, which can be thought of as the ‘neuroendocrine transducer’ of the 
light-dark cycle.  Thus, in healthy individuals, plasma melatonin levels are high during night 
sleep and low during the waking day.  Night-time exposure to bright light causes an acute 
suppression of pineal melatonin synthesis (2); this effect is used to assess the integrity of the 
retinal-SCN-pineal pathway (3).  Melatonin is hydroxylated/sulphated to 6-
sulphatoxymelatonin (aMT6s), primarily in the liver (4); aMT6s is subsequently excreted in 
the urine, where its profile mirrors that of plasma melatonin (5).  
Sleep-wake disturbances are common in patients with cirrhosis (6-8) but the 
pathophysiology remains unknown.  As melatonin is metabolized in the liver, it has been 
hypothesized that circadian sleep regulation might be implicated.  Indeed, certain reported 
abnormalities, including high day-time plasma melatonin concentrations (9,10), low urinary 
aMT6s concentrations (11) and a reduction in the clearance of exogenously administered 
melatonin (12), support this hypothesis.  However, other reported abnormalities, for example 
delays in the nocturnal rise of plasma melatonin and in its time to peak (9, 13), can not be 
explained by impairment of hepatic metabolism but might indicate dysfunction of the central 
circadian clock, and hence circadian timing. 
 
The primary aim of this study was to determine the aetiology of the abnormalities of the 
plasma melatonin profile observed in patients with cirrhosis and, specifically, to assess the 
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role of: 
1. Central circadian output, by: i) simultaneous assessment of the 24-hour rhythm of two 
reliable markers of the hypothalamic clock phase, i.e. plasma melatonin/cortisol, and ii) 
measurement of the plasma melatonin response to nocturnal administration of bright light; 
2. Hepatic melatonin metabolism, by: i) comparison of the plasma melatonin and urinary 
aMT6s 24-hour profiles; ii) measurement of plasma melatonin clearance. 
The secondary aim was to assess the contribution of circadian regulation to the sleep-wake 
abnormalities observed in this patient population. 
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PATIENTS AND METHODS 
Study subjects  
The patient population comprised 20 consecutively enrolled individuals of mean (range) age 
59 (39-77) yr, with biopsy-proven cirrhosis, which was alcohol-related in the majority.  The 
functional severity of the liver injury was assessed using Pugh’s modification of the Child 
grading system (14).  Patients were further classified as having compensated (Pugh’s score 
≤7; n=15) or decompensated (Pugh’s score >7; n=5) disease.   
Patients were excluded from the study if they had misused alcohol in the preceding 6 
months, had an estimated glomerular filtration rate of < 80 ml/min, a history of insulin-
dependent diabetes mellitus, significant head injury, cardio- or cerebro-vascular disease, 
significant neurological/psychiatric co-morbidity, corrected visual acuity of less that 6/6; if 
they were taking neuroactive medication/medication known to affect sleep and/or melatonin 
production, had travelled across more than two time zones in the preceding three months or 
undertaken shift work in the preceding five years or were not sufficiently robust to undergo 
the study procedures.   
The reference population comprised nine healthy volunteers of mean age 60 (38-84) 
yr.  None drank alcohol in excess of 20 g/day, had corrected visual acuity of less that 6/6, 
were taking prescription medication, or had travelled or undertaken shift work as defined 
above.   
 
Study design 
Individual studies were conducted over one 15-day period, in three separate locations viz: the 
Royal Free Hospital, London (clinical evaluation, sleep questionnaire), the patients’ homes 
(sleep diaries, actigraphy and screening urinary aMT6s profile) and the Clinical Investigations 
Unit (CIU) of the University of Surrey (plasma melatonin/cortisol profiles; urinary aMT6s 
profile; plasma melatonin response to light) (Table 1).   
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Subjects were asked to refrain from taking caffeinated/alcohol-containing beverages 
and to avoid strenuous exercise and exposure to bright natural light from day 12 onwards.  
Controls were exercised for both light and posture during the time spent in the CIU (Table 2).  
A maximum of three subjects were studied at any one time, to allow close surveillance and to 
ensure compliance.   
 
Sleep wake profile (Days 1-12) 
• Subjective sleep quality (Day 1).  Subjects were asked to complete the Pittsburgh Sleep 
Quality Index (PSQI) (15).  This is a self-administered questionnaire and is used to assess 
subjective sleep quality over the preceding month; total PSQI scores of >5 (range 0-21) 
identify ‘poor’ sleepers (15). 
• Sleep diaries.  Subjects kept individual sleep diaries for 12 consecutive days, in which 
they recorded their bed time, the time they started trying to sleep, their sleep onset, wake-
up and get-up times and the number of naps they took during the following day (16). 
• Actigraphy.  An actigraph is a device that records movement by means of an 
accelerometer.  Its use in sleep studies is based on the simple assumption that lack of 
movement equates to sleep.  The accuracy of this assumption is increased substantially if 
actigraphy is used in conjunction with sleep diaries.  In this study, an Actiwatch® 
(Cambridge Neurotechnology Ltd., Cambridge, UK), which is the size of a wrist-watch, 
was worn on the non-dominant wrist throughout the 12 days, except when showering or 
bathing.  The monitors were set to record for 60-second epochs and were downloaded at 
the end of the complete recording period.  Quantitative information on the variables trying 
to start to sleep and wake-up time was obtained from the corresponding sleep diary and 
entered into the manufacturer’s program for calculation of the following indices: actual 
sleep time (duration in hours); sleep latency (time to fall asleep); sleep efficiency 
(100*[actual sleep time/{wake-up time - trying to start to sleep time}]); immobile time 
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(time spent immobile between trying to start to sleep and wake-up time, as a percentage); 
night activity (total number of activity counts between trying to start sleep and wake-up 
times); fragmentation index, an indicator of restlessness (the sum of percentage time spent 
moving and the percentage immobility phases of 1-min length) (17).   
 
Urinary aMT6s profile (Days 1-3; 13-14)  
Two separate urine collections were undertaken: 
- Days 1-3: to determine the timing for light exposure (vide infra); 
- Days 13-14: to determine plasma melatonin clearance. 
Sequential urine samples were collected at 4-hour intervals during the day and 8-hour 
intervals overnight.  Aliquots of 3 ml were extracted from each individual collection and kept 
at -20 0C until assayed for aMT6s, using a radioimmunoassay (RIA) (18).  The intra-assay 
coefficients of variation (CV) ranged from 10-11%; the inter-assay CV ranged from 6-12%; 
the limit of detection was 0.3 ng/mL.  The total 24-hour urinary aMT6s output was obtained.  
The urinary aMT6s profile was evaluated using cosinor analysis, which is based on the least 
square approximation of the time series using a cosine function with a period of 24 hr (19).  If 
the function fits the time series, the latter is deemed to have a sinusoidal 24-hour rhythm and a 
number of so-called ‘cosinor’ parameters can be reliably obtained.  Data were accepted if the 
probability of the cosinor fit (p) was <0.05 (19).  The circadian parameter acrophase time - 
maximum of the fitted cosinor function, or time of the peak urinary aMT6s concentration - 
was obtained and classed as delayed if it occurred after 06:00 (20), regardless of sleep-wake 
timing. 
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Plasma melatonin and cortisol profiles (Days 13-14) 
Venous blood samples for measurement of plasma melatonin/cortisol concentrations were 
obtained hourly between 18:00 and 10:00 and two-hourly between 10:00 and 18:00, between 
days 13-14.   
Assays 
Plasma melatonin was measured using a RIA (21); the intra-assay CV ranged from 7-14%; 
the inter-assay CV ranged from 9-11%; the limit of detection was 2.6 pg/mL.  Plasma cortisol 
was also measured using a RIA (22); the intra-assay CV ranged from 5-12%; the inter-assay 
CV ranged from 8-15%; the limit of detection was 10.5 nmol/L.   
Cosinor analysis 
Plasma melatonin/cortisol profiles were examined by cosinor analysis (19); the data were 
accepted if the probability of the cosinor fit (p) was < 0.05 for melatonin and < 0.2 for 
cortisol, because of the more erratic nature of its rhythm (23).  The following parameters were 
obtained: acrophase time: maximum of the fitted cosinor function, or time of the peak plasma 
melatonin/cortisol concentration; mesor: average plasma melatonin/cortisol concentration 
over the 24 hr and amplitude: difference between the mesor and the acrophase plasma 
melatonin/cortisol concentrations.  
Onset/Offset analysis 
The onset and offset of the plasma melatonin and cortisol rhythms were defined as the time 
points, on the rise and fall of the concentration-time curve, when the plasma concentrations 
equalled 25% of the peak concentration (24); these parameters could only be calculated in 
subjects with a discernable peak on inspection.  The time interval between the rhythm onset 
and offset was defined as the peak duration.   
 
Melatonin clearance 
The area under the curve (AUC) of the plasma melatonin profile was calculated by integrating 
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point plasma concentrations over the time interval between consecutive samples.  Estimates 
of plasma melatonin clearance (L/Kg/hr) were obtained, based on the assumption that aMT6s 
was the only metabolite: 
        k [24-hour urinary aMT6s output (ng)]    
24 [average plasma melatonin (pg/ml)][body weight (kg)] 
  
where k = aMT6s molecular weight /melatonin molecular weight  
The overnight (23:00-08:00) clearance was also calculated, using matched timed plasma/urine 
samples. 
 
Sleep-circadian phase 
The phase relationship between circadian and sleep rhythms was assessed by subtracting the 
average wake-up time over the 12 monitored days from the plasma melatonin rhythm onset 
time (reference range: 12.5-17.1 hr [25]). 
 
Light suppression test (Day 15) 
Light administration time was standardized so that individuals were exposed to light during 
the rising phase of their plasma melatonin rhythm; this was assumed to occur 2.5-4.5 hr prior 
to the urinary aMT6s acrophase, estimated using the urine collections performed on days 1-3 
(26). 
Pupils were dilated using 0.5% topical tropicamide.  Subjects sat in front of a light 
sphere (45 cm diameter, Apollo Lighting) for 30 min, with their head on a chin rest; they kept 
their eyes open and looked straight ahead (27).  White light (4.1*1014 photons/cm2/second) 
was generated by a metal halide arc lamp source (Enlightened Technology Associates, Inc., 
Fairfax, VA, USA), and delivered via a fibre-optic bundle (27).  Blood was taken every 15 
min for 90 min from the beginning of light administration.   
Maximal melatonin suppression was defined as the percentage decrease in plasma 
melatonin concentration after 30 min of light exposure (27).  An average of the point 
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suppression values was also calculated; individuals with negative averages were classed as 
showing no response.  
 
Statistical analysis 
Data are presented as mean ± 1SD or SEM (range).  The distribution of variables was tested 
for normality using the Shapiro-Wilk’s W test.  Differences between normally/non-normally 
distributed variables were examined using the Student’s t/Mann-Whitney U test.  Categorized 
indices were compared by the Maximum Likelihood χ2 or Fisher’s exact test, as appropriate.  
Correlations between indices were tested using the Spearman's R.   
 
Ethics 
The study was conducted according to the Declaration of Helsinki (Hong Kong Amendment) 
and Good Clinical Practice (European Guidelines).  The protocol was approved by the Royal 
Free Hampstead NHS Trust Ethics Committee and the University of Surrey Ethics 
Committee.  All participating subjects provided written, informed consent.  
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RESULTS 
Subject characteristics and sleep behaviour 
Fourteen (70%) of the 20 patients enrolled were classed as Child’s grade A, four (20%) as 
grade B and two (10%) as grade C; of these, 15 (75%) were further classified as having 
compensated and 5 (25%) as having decompensated disease.  The patients and the healthy 
volunteers had similar age and gender distributions (Table 3).   
Sleep quality was generally impaired in the patients compared to the healthy 
volunteers (PSQI abnormal: 70% vs. 33%, p=0.07; actigraphy night activity: 11380±12089 vs. 
5509±2025 counts, p=0.07; actigraphy fragmentation index: 41±19 vs. 32±7, p=0.08); the 
mean actigraphy immobile time was significantly decreased (79±11% vs. 86±3%, p=0.04) 
(Table 3).  Sleep timing was generally delayed in the patients; the mean wake-up time was 
significantly delayed (07:42±02:00 vs. 06:36±00:54 hr; p=0.03) (Table 3).   
 
Circadian profiles in healthy volunteers and patients with cirrhosis  
Urinary aMT6s 
Cosinor analysis showed an acceptable fit in all subjects.  The mean urinary aMT6s acrophase 
was delayed by approximately 1.5 hr in the patients compared to the healthy volunteers, but 
the difference was not significant (05:12±02:24 vs. 03:48±01:30; p=0.13).  The urinary 
aMT6s acrophase was abnormally delayed (after 06:00) in eight (40%) patients but in none of 
the healthy volunteers (p=0.007).   
Plasma melatonin 
Cosinor analysis showed a significant fit in seven (78%) healthy volunteers and in 19 (95%) 
patients; onset/offset analysis was possible in seven (78%) healthy volunteers and in 18 (90%) 
patients.  There were no significant/trend differences in plasma melatonin mesor or amplitude 
between patients and healthy volunteers (Table 4).  The plasma melatonin rhythm was 
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delayed in the patients compared with the healthy volunteers, the delay affecting the rhythm 
onset (p=0.09), its acrophase (p=0.01) and its offset (p=0.08) (Table 4, Figure 1).  No 
significant/trend differences were observed in the peak duration. 
Patients with decompensated cirrhosis showed trend delays in plasma melatonin 
rhythm onset (24:21±02:12 vs. 22:29±01:14, p=0.08) and in urinary aMT6s acrophase time 
(06:45±01:49 vs. 04:45±02:26, p=0.07) compared with their compensated counterparts; in 
addition, they had a significantly higher plasma melatonin mesor (47.5±15.3 vs. 31.2±20.6 
pg/ml, p=0.05).   
Significant correlations were observed between plasma melatonin rhythm parameters 
and stand-alone/composite indices of hepatic dysfunction (Table 5).   
Plasma cortisol 
Cosinor analysis showed an acceptable fit in eight (89%) healthy volunteers and in 18 (90%) 
patients.  Onset/offset analysis could be performed in all subjects; however, in two (22%) 
healthy volunteers and seven (35%) patients the plasma cortisol rhythm offset occurred after 
18:00, beyond sampling time, thus the parameters offset and duration could not be obtained.  
There were no significant/trend differences in plasma cortisol mesor or amplitude between 
patients and healthy volunteers (Table 4).  The plasma cortisol rhythm was delayed in the 
patients compared to the healthy volunteers, the delay affecting the rhythm onset (p=0.02) and 
its acrophase (p=0.06) (Table 4).  No significant difference was observed in the timing of the 
rhythm offset between patients and healthy volunteers (Table 4); the duration of the peak was 
significantly shorter in the 13 patients compared to the seven healthy volunteers in whom the 
parameter was obtained (Table 4). 
No significant/trend differences in plasma cortisol rhythm parameters were observed 
between patients with compensated and decompensated cirrhosis.  However, a significant 
correlation was observed between plasma cortisol acrophase time and the Pugh’s score 
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(R=0.49, p<0.05). 
Light suppression 
The time course of the mean plasma melatonin suppression profile of patients and healthy 
volunteers was similar, with minimal plasma melatonin levels (maximal suppression) 30 min 
after the beginning of light administration.  However, patients showed a blunted though not 
significantly different maximal plasma melatonin response (12±19% vs. 24±15%, p=0.09; 
Figure 2); four patients showed no light response at all (23% vs. 0%, p=0.03). 
Relationships between circadian variables 
No significant differences were observed between patients and healthy volunteers in the time 
interval between the plasma melatonin and the urinary aMT6s acrophase (1.3±1.8 vs. 1.6±0.8 
hr, p>0.05), the AUC of the plasma melatonin profile or the 24-hour plasma melatonin 
clearance.  However, patients showed a significantly reduced overnight plasma melatonin 
clearance (0.11±0.06 vs. 0.21±0.13, p=0.02).   
A significant correlation was observed between the plasma melatonin and plasma 
cortisol acrophase times (R=0.46, p<0.05).  Finally, significant, negative correlations were 
observed between the plasma melatonin/cortisol acrophase times and the maximal 
suppression at 30 min from the beginning of light administration (R=-0.46; R=-0.43, p<0.05; 
Figure 3).   
 
Circadian profiles and sleep behaviour 
No significant differences in plasma melatonin profile indices were observed between 
subjects classified as ‘good’ or ‘poor sleepers’ on the basis of the PSQI.  Similarly, no 
significant correlations were observed between plasma melatonin profile and actigraphic 
indices. 
A significant correlation was observed between the plasma melatonin rhythm onset 
time and habitual wake-up time in the healthy volunteers, but not in the patients with 
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cirrhosis, in whom these parameters showed greater variability (Figure 4).  Four (22%) 
patients with cirrhosis had a phase relationship which was either shorter (n = 1) or longer (n = 
3) than the reference range, a feature not observed in the healthy volunteers (Figure 4).   
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DISCUSSION 
Patients with cirrhosis exhibited delays in both plasma melatonin and cortisol 24-hour 
rhythms and a reduction in their plasma melatonin response to light.  These changes indicate 
the presence of central circadian disruption.  In contrast, there was limited evidence of 
impaired hepatic melatonin metabolism.  Patients with cirrhosis also showed a degree of 
misalignment between sleep and circadian timing but there was no obvious association 
between circadian abnormalities and impaired sleep quality.  
 
Melatonin metabolism 
The duration of the plasma melatonin peak and the time interval between the plasma 
melatonin and the urinary aMT6s peaks were comparable in patients and healthy volunteers 
and no differences were observed in the average AUC of the plasma melatonin profile or in 
the 24-hour melatonin clearance.  Interestingly, overnight plasma melatonin clearance was 
reduced, probably indicating that some degree of impairment in hepatic disposition does exist 
in these patients but is only apparent when the plasma melatonin concentrations are high.  
This hypothesis is supported by the significant positive correlations observed between indices 
of increasing hepatic dysfunction and increases in the plasma melatonin mesor - the average 
concentration over the 24 hr - and delays in the offset of the plasma melatonin rhythm.   
Thus, these data, which were obtained in patients with mild to moderately 
decompensated disease, would seem to indicate that the overall contribution of impaired 
hepatic metabolism to the disruption in the plasma melatonin profile in patients with cirrhosis 
is small.  However, the effect may be more significant, and hence more evident, in patients 
with more severe decompensation.  The demands of this study were such that individuals with 
end-stage liver disease could not be included.   
There are few, if any, published studies with which to compare these data.  Steindl and 
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co-workers (11) reported a reduction in urinary aMT6s output in 21 patients with cirrhosis, 
which they interpreted as showing impairment in hepatic melatonin catabolism yet were 
unable to show any relationship between the urinary MT6s concentrations and various indices 
of hepatic function.  Their observations were based, however, on measurement of urinary 
aMT6s in a single, 8-hour overnight urine collection which, as such, will not have provided 
representative data.   
 
Circadian clock output 
Significant delays were observed in the rising phase of the plasma melatonin profile in the 
patients with cirrhosis, resulting in an overall shift of the 24-hour rhythm towards a later hour.  
The shift was more pronounced in patients with decompensated disease.  These findings are 
substantially in line with those of Steindl and co-workers (9), who originally hypothesised 
that the clock output might be abnormal in this patient population.  The attenuated melatonin 
response to light observed in the present study provides further and more robust evidence of 
central circadian disruption.     
Significant delays were also observed in the rising phase the plasma cortisol profile in 
the patients with cirrhosis.  These findings contrast with those of Bernardi and colleagues (28) 
and Velissaris and colleagues (10).  However, these studies can be criticised for two reasons: 
i) the number of plasma samples obtained for cortisol measurement was smaller than required 
for accurate estimates of rhythm timing (29); ii) controls were not exercised for light 
exposure, which is important, as even ordinary room light has been shown to have phase-
resetting effects on the cortisol rhythm, mediated via the hypothalamic clock (30).  The 
reduced duration of the plasma cortisol peak observed in patients with cirrhosis in this study 
is difficult to interpret.  Shortening of plasma cortisol peaks has been reported in healthy 
volunteers in response to chronic exposure to short nights (31).  It is possible that chronically 
interrupted night rest might produce a similar result. 
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The observed delays in plasma melatonin and cortisol rhythms occurred in parallel, 
providing further evidence for dysfunctional clock output.  Piscaglia and colleagues (13) 
obtained plasma melatonin and plasma fibrinolysis function profiles in patients with cirrhosis 
and healthy volunteers.  Patients showed a delay in the plasma melatonin acrophase but not in 
that of fibrinolysis indices, leading to authors to conclude that circadian clock function is 
preserved in this patient population (13).  The choice of plasma fibrinolysis as a circadian 
marker is questionable because the nature of plasma fibrinolysis rhythmicity and, more 
importantly, its relation to the SCN output remain unknown.  In contrast, plasma melatonin 
and plasma cortisol are recognised, direct markers of clock phase (32).   
 
Pathophysiology  
The cause of the retinal-SCN-pineal pathway dysfunction, in patients with cirrhosis, remains 
unknown, but hypotheses can be formulated.  Low-grade swelling has been observed in the 
retinal Müller cells in patients with cirrhosis and associated with changes in the 
electroretinogram and in colour discrimination (33).  It is not known whether the 
photoreceptors or the retinal ganglion cells are also affected but, if so, this might impinge on 
the process of light entrainment.  In this study, delays in the plasma melatonin acrophase were 
associated with blunted light-induced suppression responses, suggesting that the former might 
be a consequence of a reduced sensitivity to light.  Similar abnormalities have been reported 
in blind subjects (34).  Central GABAergic/glutamatergic neurotransmission is also disrupted 
in patients with cirrhosis (35).  GABA and glutamate are involved in the transmission of the 
photic stimulus from the retina to the SCN (36).  Thus, increased GABAergic tone might 
disrupt the retinal-SCN pathway and, in consequence, the output of the clock. 
 
Clinical relevance 
In this study, patients with cirrhosis showed a degree of misalignment between their sleep and 
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their circadian timing.  The abnormal phasing of internal rhythms relative to one another, 
especially if long-standing, has been shown to have serious adverse effects on safety, 
performance and health.  Shift workers, for example, have increased incidences of the 
metabolic syndrome, heart disease and even cancer (37, 38).  Therefore, the long term effects 
of circadian delays and circadian-sleep misalignment in patients with cirrhosis are certainly 
worthy of further investigation.   
However, there was no obvious association between circadian abnormalities and 
impaired sleep quality, indicating that the sleep disturbances observed in these patients are 
unlikely to depend on circadian derangement (39).  Alternative pathophysiological pathways, 
in particular homeostatic sleep regulation, need to be explored. 
 
In conclusion, the plasma melatonin profile abnormalities exhibited by patients with mild to 
moderately decompensated cirrhosis are predominantly central in origin, and are substantially 
unrelated to the sleep disturbances observed in this patient population. 
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What is current knowledge  
- Sleep-wake disturbances are common in patients with cirrhosis. 
- Plasma melatonin profile abnormalities have also been described in these patients, and 
generally attributed to impaired hepatic melatonin metabolism.  
- It has been hypothesised that plasma melatonin profile abnormalities might play an 
important role in the pathogenesis of sleep-wake disturbances in patients with cirrhosis.  
What is new here  
- The plasma melatonin profile abnormalities observed in patients with cirrhosis reflect, in 
the main, central circadian clock dysfunction.  
- The contribution of impaired hepatic melatonin metabolism to the changes in plasma 
melatonin profiles in patients with mild to moderately decompensated cirrhosis is small. 
- Melatonin profile abnormalities do not offer a comprehensive explanation to the sleep-
wake disturbances exhibited by these patients and alternative pathophysiological 
pathways should be sought. 
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Figure Legends 
Figure 1.  Average (± SEM) plasma melatonin profiles with accepted cosinor fit in the 
healthy volunteers and the patients with cirrhosis.  The average, calculated rhythm onset, 
acrophase times and rhythm offset are indicated by labelled arrows.  Patients showed an 
overall delay in the plasma melatonin rhythm, affecting both the rising and the declining 
phase.    
 
Figure 2.  Mean (± SEM) plasma melatonin suppression, 15 to 90 min after the beginning of 
light administration in the healthy volunteers and the patients with cirrhosis.  The response 
profile was similar in the two groups, with minimal plasma melatonin levels (maximal 
suppression) at 30 min from the beginning of light administration; however, patients showed 
an attenuated plasma melatonin response to light at all times.  * p=0.09 
 
Figure 3. Correlation between plasma melatonin suppression at 30 min from the beginning of 
light administration and plasma melatonin acrophase time in the healthy volunteers and the 
patients with cirrhosis.  The grey shade highlights a substantially ‘normal’ area, where 
suppression is >15% and the acrophase occurs before 05:00.  In general, patients with delayed 
plasma melatonin acrophase time also had poor plasma melatonin responses to light (red 
squares outside the gray-shaded area).   
 
Figure 4.  Relationship between the plasma  melatonin rhythm onset time and habitual wake-
up times in the healthy volunteers (left panel) and in the patients with cirrhosis (right panel).  
The correlation between the two parameters was significant in the healthy volunteers but not 
in the patients.  Four patients had a phase relationship (plasma melatonin rhythm onset time - 
habitual wake-up time) which was either shorter (square) or longer (circles) than the reference 
12.5-17.1 hr range (24). 
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